Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| AEARCTR-0013549 | Registry Identifier | AEA RCT Registry (socialscienceregistry.org) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Southern California | OTHER |
| Bowdoin College | OTHER |
| Abdul Latif Jameel Poverty Action Lab | OTHER |
| Minnesota Management and Budget |
Not provided
Not provided
Not provided
Not provided
This study will test e-mails to encourage engagement with the Minnesota prescription monitoring program (PMP/PDMP) and will evaluate the effect of these e-mails on PMP/PDMP use and controlled substance prescribing.
Drug overdose deaths have skyrocketed in recent years, and many overdoses continue to involve prescribed medications like opioids and stimulants. At the same time, state prescription drug monitoring programs (PDMPs), which help clinicians prescribe these medications safely, remain underused. In Minnesota, 32% of opioid prescriptions are written by clinicians who do not use the PDMP. In many states, including Minnesota, policymakers have limited tools to raise PDMP use even though it is often required under state law. To address this policy dilemma, this study will test e-mails designed to facilitate PDMP use and evaluate their effects on PDMP use and controlled substance prescribing. This study will include a projected 7,126 physician and physician assistant prescribers of opioids and other controlled substances who lack active PDMP accounts, never query the PDMP, or query the PDMP infrequently relative to their prescribing volume. To generate evidence on clinician motivation for responding to encouragement, the study will randomly vary messaging to focus on legal requirements to use the PDMP vs. clinical benefits of the PDMP.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Legal Mandate Messaging | Experimental |
| |
| Clinical Benefit Messaging | Experimental |
| |
| Control | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PDMP Legal Mandate E-mail | Behavioral | E-mails highlighting the state's legal requirements to use the PDMP. There will be one initial email and one follow-up email one month later. |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of PDMP Engagement | An indicator for increased PDMP engagement during the 2-month period after the first e-mails were sent. It will indicate whether the level of engagement rose from the baseline level that resulted in the clinician's enrollment into the study. For clinicians who lacked an account, the outcome will indicate whether they created one; for clinicians with an inactive account, the outcome will indicate whether they reactivated it. For those who never searched, it will indicate any search, and for those who rarely searched, it will indicate whether their search rate rose. | 2 months |
| Volume of Potentially Guideline-discordant Opioid Prescribing | A composite of several measures of potentially guideline-discordant opioid prescribing. These will include:
| 2 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Adam Sacarny, PhD | Columbia University | Principal Investigator |
| Mireille Jacobson, PhD | University of Southern California | Principal Investigator |
| Tatyana Avilova, PhD | Bowdoin College | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Columbia University Irving Medical Center | New York | New York | 10032 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41632198 | Derived | Sacarny A, Avilova T, Williamson I, Merrick W, Jacobson M. Prescription Drug Monitoring Program Reminder Emails, Program Use, and Prescribing: A Randomized Clinical Trial. JAMA Health Forum. 2025 Dec 5;6(12):e255623. doi: 10.1001/jamahealthforum.2025.5623. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D063487 | Prescription Drug Misuse |
| ID | Term |
|---|---|
| D000076064 | Drug Misuse |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| UNKNOWN |
| Minnesota Board of Pharmacy | OTHER |
Clinicians will be assigned at random to one of three arms: PDMP legal mandate e-mails, PDMP clinical benefit emails, or a control group.
Not provided
Not provided
Not provided
Not provided
| PDMP Clinical Benefit E-mail | Behavioral | E-mails highlighting the clinical benefits of having access to the PDMP and checking the PDMP before prescribing opioids. There will be one initial email and one follow-up email one month later. |
|